2025
Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes
Zohora F, Nazari M, Sinusas A. Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes. Current Cardiology Reports 2025, 27: 61. PMID: 40009333, DOI: 10.1007/s11886-025-02197-9.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter defibrillatorPositron emission tomographyImplantable cardioverter defibrillator placementMyocardial sympathetic denervationRisk stratificationSympathetic denervationIschemic heart diseaseHeart failurePrevention of sudden cardiac deathRisk stratification of patientsHeart diseaseOptimal risk stratificationLow ejection fractionStratification of patientsSympathetic nerve densityImprove risk stratificationHeart failure patientsPositron emission tomography radiotracersPredicting sudden cardiac deathPositron emission tomography tracersPrognostic benefitEjection fractionClinically practical approachNerve density
2024
Beyond HMAs: Novel Targets and Therapeutic Approaches
Getz T, Bewersdorf J, Kewan T, Stempel J, Bidikian A, Shallis R, Stahl M, Zeidan A. Beyond HMAs: Novel Targets and Therapeutic Approaches. Seminars In Hematology 2024, 61: 358-369. PMID: 39389839, DOI: 10.1053/j.seminhematol.2024.08.001.Peer-Reviewed Original ResearchAcute myeloid leukemiaDelays progression to acute myeloid leukemiaHeterogeneous group of clonal hematopoietic disordersGroup of clonal hematopoietic disordersMolecular International Prognostic Scoring SystemRandomized phase 3 clinical trialProgression to acute myeloid leukemiaInternational Prognostic Scoring SystemLower-risk MDS patientsRisk stratification of patientsPhase 3 clinical trialsCombination of azacitidineHypomethylating agent combinationsCurrent treatment landscapeFirst line therapyPrognostic Scoring SystemBiomarker-directed therapiesClonal hematopoietic disordersLack of therapeutic agentsStratification of patientsEarly phase trialsErythropoiesis stimulating agentsTreated with therapiesVariable clinical featuresStandard of carePersonalized brain circuit scores identify clinically distinct biotypes in depression and anxiety
Tozzi L, Zhang X, Pines A, Olmsted A, Zhai E, Anene E, Chesnut M, Holt-Gosselin B, Chang S, Stetz P, Ramirez C, Hack L, Korgaonkar M, Wintermark M, Gotlib I, Ma J, Williams L. Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety. Nature Medicine 2024, 30: 2076-2087. PMID: 38886626, PMCID: PMC11271415, DOI: 10.1038/s41591-024-03057-9.Peer-Reviewed Original ResearchBehavioral therapyFunctional magnetic resonance imaging protocolTask-free functional connectivityHeterogeneity of depressionBrain circuit dysfunctionResponse to pharmacotherapyTheoretical taxonomyAttentional circuitsNeurobiological dysfunctionBehavioral performanceCircuit dysfunctionCognitive tasksSubcortical regionsFunctional connectivityTask-freeAnxietyDepressionTheory-drivenPharmacotherapyStratification of patientsMagnetic resonance imaging protocolScoresPsychiatryDysfunctionClinical careHypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis
Zheng L, Tian S, Yang C, Li B, Jia G, Liu Y, Sun R, Wang X, Deng J, Zhang M, Cui L, Guo C, Zhou X, Leung P, Bowlus C, Gershwin M, Shang Y, Han Y. Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis. Clinical Gastroenterology And Hepatology 2024, 22: 1265-1274.e19. PMID: 38354969, DOI: 10.1016/j.cgh.2024.01.039.Peer-Reviewed Original ResearchPrimary biliary cholangitisPoor clinical outcomesAssociated with poor clinical outcomesHigh-risk patientsCirrhosis-related complicationsClinical outcomesTotal cholesterolBiliary cholangitisGLOBE scoreUntargeted lipidomicsLiver transplantationValidation cohortHealthy controlsRisk of poor clinical outcomesLipid metabolismBaseline total cholesterolComplete clinical dataLiver-related deathStratification of patientsAccurate stratification of patientsBaseline TC levelHigh-risk groupDysregulation of lipid metabolismAssociated with dysregulationUpregulated lipidsInsulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease
Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Ochoa Chaar C. Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease. Annals Of Vascular Surgery 2024, 102: 25-34. PMID: 38307234, DOI: 10.1016/j.avsg.2023.11.044.Peer-Reviewed Original ResearchInsulin-requiring diabetes mellitusPeripheral arterial diseaseDiabetes mellitusInfrainguinal bypassInsulin requirementsArtery diseaseRisk of MALEBypass surgeryImpact of insulin useRates of primary patencyVascular Quality Initiative databaseOutcomes of patientsPeripheral arterial bypass surgeryInfrainguinal bypass surgeryStratification of patientsCrude rateElevated hemoglobin A1cArtery bypass surgeryAssociation of DMChronic limb-threatening ischemiaIncreased risk of MALEVascular Quality InitiativeLower extremity revascularizationAdverse limb eventsLimb-threatening ischemiaHER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Li Z, Filho O, Viale G, dell'Orto P, Russo L, Goyette M, Kamat A, Yardley D, Abramson V, Arteaga C, Spring L, Chiotti K, Halsey C, Waks A, King T, Lester S, Bellon J, Winer E, Spellman P, Krop I, Polyak K. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. Journal Of Clinical Investigation 2024, 134: e176454. PMID: 38300710, PMCID: PMC10977978, DOI: 10.1172/jci176454.Peer-Reviewed Original ResearchPathological complete responseHER2-positive breast cancerHER2 heterogeneityBreast cancerEarly-stage HER2-positive breast cancerHER2-targeted therapyPre-treatment tumorsErbB signalingHER2-targeted antibodiesBasal-like featuresHER2 protein levelsStratification of patientsNational Cancer InstituteNeoadjuvant trialsComplete responseResidual tumorT-DM1Copy number heterogeneityTrastuzumab emtansineERBB2 mRNAImmune infiltrationDownstream pathway componentsClinical challengeClinical trialsTumorImaging Cardiac and Vascular Inflammation
Tavakoli S, Sadeghi M. Imaging Cardiac and Vascular Inflammation. 2024, 511-530. DOI: 10.1093/med/9780190095659.003.0025.Peer-Reviewed Original ResearchRisk stratification of patientsStratification of patientsPathogenesis of cardiovascular diseaseEvaluating cardiovascular pathologiesPrecision medicine toolsRisk stratificationClinical studiesEarly diagnosisInflammatory processCardiovascular diseaseMedicine toolsCardiovascular pathologyTherapeutic interventionsClinical settingImaging strategiesMolecular imagingImaging Cardiac and Vascular Inflammation
Tavakoli S, Sadeghi M. Imaging Cardiac and Vascular Inflammation. 2024, 131-133. DOI: 10.1093/med/9780197521434.003.0025.Peer-Reviewed Original ResearchRisk stratification of patientsStratification of patientsPathogenesis of cardiovascular diseaseEvaluating cardiovascular pathologiesPrecision medicine toolsRisk stratificationClinical studiesEarly diagnosisInflammatory processCardiovascular diseaseMedicine toolsCardiovascular pathologyTherapeutic interventionsClinical settingImaging strategiesMolecular imaging
2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The Oncologist 2023, 29: e507-e513. PMID: 37971411, PMCID: PMC10994263, DOI: 10.1093/oncolo/oyad300.Peer-Reviewed Original ResearchBRAF/MEK inhibitorsBRAF/MEK inhibitionImmune checkpoint inhibitorsBRAFV600E/K mutationsMEK inhibitorsCheckpoint inhibitorsClinical variablesMEK inhibitionRetrospective single-institution analysisIpilimumab/nivolumabFirst-line settingFirst-line therapyFirst-line treatmentMetastatic melanoma patientsLong-term outcomesPretreatment clinical variablesSingle-institution analysisStratification of patientsK mutationCombined BRAFECOG PSMedian OSRECIST 1.1Immunotherapy regimenClinical characteristics
2022
Hormone therapies in meningioma-where are we?
Miyagishima D, Moliterno J, Claus E, Günel M. Hormone therapies in meningioma-where are we? Journal Of Neuro-Oncology 2022, 161: 297-308. PMID: 36418843, PMCID: PMC10371392, DOI: 10.1007/s11060-022-04187-1.Peer-Reviewed Original ResearchConceptsPositive receptor statusReceptor statusSomatostatin analoguesClinical trialsHormone-related risk factorsMajority of patientsNIH Clinical Trials DatabaseClinical trials databasesStratification of patientsHormone therapyTrials databasesFuture trialsHormonal agentsSpecific therapyRisk factorsSomatostatin receptorsInclusion criteriaMEDLINE-PubMedMeningioma growthMost meningiomasTherapeutic potentialMeningiomasPatientsTherapyTrialsAn Explainable Machine Learning Approach Reveals Prognostic Significance of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy
Fahmy A, Csecs I, Arafati A, Assana S, Yankama T, Al-Otaibi T, Rodriguez J, Chen Y, Ngo L, Manning W, Kwong R, Nezafat R. An Explainable Machine Learning Approach Reveals Prognostic Significance of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy. JACC Cardiovascular Imaging 2022, 15: 766-779. PMID: 35033500, DOI: 10.1016/j.jcmg.2021.11.029.Peer-Reviewed Original ResearchConceptsNonischemic dilated cardiomyopathyBeth Israel Deaconess Medical CenterComposite endpointRight ventricular (RV) dysfunctionCardiovascular hospitalizationRisk prediction modelAdverse outcomesRisk markersMarker of adverse outcomeCardiac magnetic resonance markersRisk stratification of patientsRight ventricular dysfunctionRV ejection fractionMedical CenterFollow-up durationCardiac magnetic resonanceEnd-diastolic volumeStratification of patientsArea under the curveAll-cause deathHigh-risk thresholdVentricular dysfunctionEjection fractionNonischemic cardiomyopathyPrognostic significance
2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D’Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021, 592: 450-456. PMID: 33762733, PMCID: PMC8046670, DOI: 10.1038/s41586-021-03362-0.Peer-Reviewed Original ResearchConceptsNon-alcoholic steatohepatitisNon-viral hepatocellular carcinomaAnti-PD1 treatmentT cellsHepatocellular carcinomaNASH-HCCImmune surveillanceRandomized phase III clinical trialsPhase III clinical trialsAberrant T cell activationAnti-PDL1 treatmentAnti-tumor surveillanceStudy of immunotherapyDepletion of CD8Advanced hepatocellular carcinomaTumor immune surveillanceStratification of patientsBiomarker-based stratificationT cell activationAdjuvant treatmentOverall survivalTNF neutralizationDeath-1Immune therapyTherapeutic immunotherapy
2020
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI
Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology 2020, 31: 2737-2746. PMID: 33123796, PMCID: PMC8043967, DOI: 10.1007/s00330-020-07381-9.Peer-Reviewed Original ResearchConceptsTumor response criteriaOverall survivalAdvanced-stage HCCDisease progressionSorafenib therapyDisease controlResponse criteriaCox proportional hazards regression modelAdvanced-stage hepatocellular carcinomaProportional hazards regression modelsDCE-MRIInitiation of sorafenibTumor response analysisMultivariable Cox regressionIndependent risk factorMethodsThis retrospective analysisIndependent prognostic factorInitiation of treatmentKaplan-Meier analysisKaplan-Meier curvesHazards regression modelsLog-rank testStratification of patientsTotal tumor volumeArterial phase MRIRecommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists
Aminorroaya A, Vasheghani-Farahani A, Masoudkabir F, Roayaei P. Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists. Journal Of Interventional Cardiac Electrophysiology 2020, 60: 1-7. PMID: 32712900, DOI: 10.1007/s10840-020-00837-4.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter-defibrillatorHypertrophic cardiomyopathySudden cardiac death risk stratificationEuropean Society of Cardiology guidelinesPrimary prevention implantable cardioverter-defibrillatorRisk stratification of patientsAmerican College of Cardiology Foundation/American Heart AssociationImplantable cardioverter-defibrillator implantationHigh-risk patientsStratification of patientsImplantation of primary prevention implantable cardioverter-defibrillatorsCardioverter-defibrillator implantationCardiology guidelinesRisk patientsVentricular arrhythmiasClinical outcomesCardiac deathCardioverter-defibrillatorHeart AssociationAmerican CollegePrimary preventionPatientsCare practitionersEuropean Society
2019
Early Prognostication of 1-Year Outcome After Subarachnoid Hemorrhage: The FRESH Score Validation
Witsch J, Kuohn L, Hebert R, Cord B, Sansing L, Gilmore EJ, Hwang DY, Petersen N, Falcone GJ, Matouk C, Sheth KN. Early Prognostication of 1-Year Outcome After Subarachnoid Hemorrhage: The FRESH Score Validation. Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104280. PMID: 31326270, DOI: 10.1016/j.jstrokecerebrovasdis.2019.06.038.Peer-Reviewed Original ResearchConceptsSpontaneous subarachnoid hemorrhageModified Rankin ScaleLong-term outcomesSubarachnoid hemorrhageUnfavorable outcomePercent of patientsExclusion of patientsStratification of patientsScore variablesAneurysmal etiologyBleeding sourceRankin ScaleFunctional outcomeMean ageEarly prognosticationPrognostication scoresStudy investigatorsHospital resourcesPatientsDisability partAneurysm coilingOutcomesHigh gradeCharacteristic curveHemorrhage
2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, Boyd Z, Miley N, Flynn S, Leveque V, Shames DS, Ballinger M, Mocci S, Shankar G, Funke R, Hampton G, Sandler A, Amler L, Mellman I, Chen DS, Hegde PS. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1). Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 115: e10119-e10126. PMID: 30297397, PMCID: PMC6205493, DOI: 10.1073/pnas.1802166115.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPD-L1 expressionImmune cellsTumor cellsCases of NSCLCHigh PD-L1 expressionHigh PD-L1 levelsSingle-agent checkpoint inhibitorsAntitumor T-cell responsesTumor-infiltrating immune cellsPD-L1 levelsEffector T cellsTumor-infiltrating lymphocytesDurable clinical responsesPD-L1 geneT cell responsesCell lung cancerStratification of patientsPoor immune infiltrationCheckpoint inhibitorsClinical responseAnticancer immunityImmune infiltrationLung cancerDesmoplastic stromaAssociation between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database
Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.Peer-Reviewed Original ResearchConceptsMetastatic-free intervalMetastatic breast cancerInitial breast cancer diagnosisBreast cancer-specific mortalityCancer-specific mortalitySubsequent metastatic diseaseBreast cancer diagnosisMetastatic diseaseFree intervalBreast cancerCancer diagnosisBreast cancer-specific survival ratesMetastatic breast cancer survivalCancer-specific survival ratesDiagnosis of MBCImproved cancer-specific survivalRecurrent metastatic breast cancerCancer-specific survivalEnd Results (SEER) databaseLow tumor gradeBreast cancer survivalChoice of treatmentStratification of patientsMethodsThe SurveillancePurposeThe prevalence
2016
Genomic predictors of biochemical failure following radical prostatectomy.
Aneja S, Yu J, Glazer P. Genomic predictors of biochemical failure following radical prostatectomy. Journal Of Clinical Oncology 2016, 34: 114-114. DOI: 10.1200/jco.2016.34.2_suppl.114.Peer-Reviewed Original ResearchPathologic T stageGleason 7 diseaseBiochemical failureRadical prostatectomyT stageProstate adenocarcinomaClinical dataPredictors of BFAggressive regional therapyClinical patient characteristicsPre-treatment PSARNA expressionStratification of patientsHierarchical logistic regression modelsLogistic regression modelsMedian followAggressive therapyPatient characteristicsCancer Genome AtlasExpression of TP53Gleason 7Median ageRegional therapyGleason scoreClinical correlates
2015
Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.
Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, Larvie M, Curry WT, Barker FG, Martuza RL, McGuone D, Oh KS, Loeffler JS, Shih HA. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. Journal Of Neurosurgery 2015, 124: 106-14. PMID: 26274991, DOI: 10.3171/2015.1.jns142228.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyDisease ProgressionFemaleFollow-Up StudiesHumansKi-67 AntigenMaleMeningiomaMiddle AgedNeoplasm Recurrence, LocalNeurosurgical ProceduresPrognosisRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentTreatment OutcomeWorld Health OrganizationYoung AdultConceptsAtypical featuresBenign meningiomasWorld Health Organization (WHO) grade I meningiomasSimpson grade IIMIB-1 labeling indexAtypical histological featuresProgression/recurrenceHigh-risk groupStratification of patientsSimpson grade resectionGrade I meningiomasMedian followConclusions PatientsActuarial rateAdditional surgeryClinical outcomesInitial treatmentHistopathological featuresPrognostic significanceHistological factorsHistological featuresGrade IGrade IIPathological diagnosisInclusion criteria
2009
Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
Garcia-Tsao G, Lim J. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. The American Journal Of Gastroenterology 2009, 104: 1802. PMID: 19455106, DOI: 10.1038/ajg.2009.191.Peer-Reviewed Original ResearchMeSH KeywordsCause of DeathDiagnostic ImagingDisease ProgressionEvidence-Based MedicineFemaleGastrointestinal HemorrhageHepatitis C, ChronicHepatorenal SyndromeHumansHypertension, PortalImmunohistochemistryLiver CirrhosisLiver FailureLiver Function TestsMaleRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival AnalysisUnited StatesUnited States Department of Veterans AffairsConceptsVariceal hemorrhageSevere complicationsHepatocellular carcinomaAcute variceal hemorrhageComplications of cirrhosisPresence of ascitesChronic liver diseaseSpontaneous bacterial peritonitisTreatment of ascitesRandomized clinical trialsTreatment of patientsStratification of patientsDifferent risk groupsQuality of lifeDecompensated patientsHepatorenal syndromeHepatitis CPortal hypertensionCirrhotic patientsProspective trialBacterial peritonitisHemodynamic alterationsLiver diseaseTreatment adherenceAscites formation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply